vs
Side-by-side financial comparison of CAMDEN NATIONAL CORP (CAC) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $64.3M, roughly 1.4× CAMDEN NATIONAL CORP). CAMDEN NATIONAL CORP runs the higher net margin — 34.0% vs 25.0%, a 9.0% gap on every dollar of revenue. Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 22.6%).
Camden National Bank is a commercial bank headquartered in Camden, Maine, operating as the principal subsidiary of Camden National Corporation, a publicly traded bank holding company. Founded in 1875, the bank became a direct, wholly owned subsidiary of the holding company following a corporate reorganization in 1984. Following the 2025 merger with Northway Financial, the combined institution has approximately $7.0 billion in assets.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
CAC vs VCEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $64.3M | $92.9M |
| Net Profit | $21.9M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | — | 24.1% |
| Net Margin | 34.0% | 25.0% |
| Revenue YoY | — | 23.3% |
| Net Profit YoY | — | 17.3% |
| EPS (diluted) | $1.29 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $64.3M | — | ||
| Q4 25 | $68.1M | $92.9M | ||
| Q3 25 | $65.4M | $67.5M | ||
| Q2 25 | $62.3M | $63.2M | ||
| Q1 25 | $60.1M | $52.6M | ||
| Q4 24 | $47.6M | $75.4M | ||
| Q3 24 | $45.0M | $57.9M | ||
| Q2 24 | $42.8M | $52.7M |
| Q1 26 | $21.9M | — | ||
| Q4 25 | $22.6M | $23.2M | ||
| Q3 25 | $21.2M | $5.1M | ||
| Q2 25 | $14.1M | $-553.0K | ||
| Q1 25 | $7.3M | $-11.2M | ||
| Q4 24 | $14.7M | $19.8M | ||
| Q3 24 | $13.1M | $-901.0K | ||
| Q2 24 | $12.0M | $-4.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% |
| Q1 26 | — | — | ||
| Q4 25 | 41.5% | 24.1% | ||
| Q3 25 | 40.5% | 5.1% | ||
| Q2 25 | 28.5% | -3.2% | ||
| Q1 25 | 10.3% | -24.3% | ||
| Q4 24 | 38.7% | 24.5% | ||
| Q3 24 | 35.2% | -4.3% | ||
| Q2 24 | 34.7% | -11.5% |
| Q1 26 | 34.0% | — | ||
| Q4 25 | 33.1% | 25.0% | ||
| Q3 25 | 32.4% | 7.5% | ||
| Q2 25 | 22.6% | -0.9% | ||
| Q1 25 | 12.2% | -21.4% | ||
| Q4 24 | 30.8% | 26.3% | ||
| Q3 24 | 29.1% | -1.6% | ||
| Q2 24 | 28.0% | -8.9% |
| Q1 26 | $1.29 | — | ||
| Q4 25 | $1.33 | $0.46 | ||
| Q3 25 | $1.25 | $0.10 | ||
| Q2 25 | $0.83 | $-0.01 | ||
| Q1 25 | $0.43 | $-0.23 | ||
| Q4 24 | $1.00 | $0.40 | ||
| Q3 24 | $0.90 | $-0.02 | ||
| Q2 24 | $0.81 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | $514.4M | — |
| Stockholders' EquityBook value | $710.0M | $354.6M |
| Total Assets | $7.0B | $488.0M |
| Debt / EquityLower = less leverage | 0.72× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | — | $101.7M | ||
| Q2 24 | — | $102.5M |
| Q1 26 | $514.4M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $710.0M | — | ||
| Q4 25 | $696.6M | $354.6M | ||
| Q3 25 | $676.4M | $321.9M | ||
| Q2 25 | $652.1M | $306.8M | ||
| Q1 25 | $640.1M | $295.5M | ||
| Q4 24 | $531.2M | $292.0M | ||
| Q3 24 | $529.9M | $257.5M | ||
| Q2 24 | $508.3M | $243.0M |
| Q1 26 | $7.0B | — | ||
| Q4 25 | $7.0B | $488.0M | ||
| Q3 25 | $7.0B | $453.3M | ||
| Q2 25 | $6.9B | $435.6M | ||
| Q1 25 | $7.0B | $424.6M | ||
| Q4 24 | $5.8B | $432.7M | ||
| Q3 24 | $5.7B | $390.4M | ||
| Q2 24 | $5.7B | $376.8M |
| Q1 26 | 0.72× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $63.9M | $15.0M | ||
| Q3 25 | $36.1M | $22.1M | ||
| Q2 25 | $6.0M | $8.2M | ||
| Q1 25 | $1.0M | $6.6M | ||
| Q4 24 | $60.9M | $22.2M | ||
| Q3 24 | $-14.5M | $10.2M | ||
| Q2 24 | $14.5M | $18.5M |
| Q1 26 | — | — | ||
| Q4 25 | $58.2M | $12.8M | ||
| Q3 25 | $35.4M | $19.5M | ||
| Q2 25 | $4.5M | $81.0K | ||
| Q1 25 | $-727.0K | $-7.6M | ||
| Q4 24 | $55.4M | $8.5M | ||
| Q3 24 | $-16.2M | $-9.2M | ||
| Q2 24 | $13.2M | $1.8M |
| Q1 26 | — | — | ||
| Q4 25 | 85.5% | 13.8% | ||
| Q3 25 | 54.1% | 28.8% | ||
| Q2 25 | 7.3% | 0.1% | ||
| Q1 25 | -1.2% | -14.5% | ||
| Q4 24 | 116.4% | 11.2% | ||
| Q3 24 | -36.0% | -15.9% | ||
| Q2 24 | 30.8% | 3.4% |
| Q1 26 | — | — | ||
| Q4 25 | 8.4% | 2.4% | ||
| Q3 25 | 1.1% | 3.9% | ||
| Q2 25 | 2.4% | 12.9% | ||
| Q1 25 | 2.9% | 27.0% | ||
| Q4 24 | 11.7% | 18.3% | ||
| Q3 24 | 3.8% | 33.5% | ||
| Q2 24 | 3.0% | 31.8% |
| Q1 26 | — | — | ||
| Q4 25 | 2.83× | 0.65× | ||
| Q3 25 | 1.70× | 4.35× | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | 4.15× | 1.12× | ||
| Q3 24 | -1.11× | — | ||
| Q2 24 | 1.21× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CAC
| Net Interest Income | $52.4M | 81% |
| Noninterest Income | $12.0M | 19% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
